{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:59:01Z","timestamp":1794887941656,"version":"4.9.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Immunization of varicella-zoster virus (VZV)-seronegative solid organ transplant (SOT) patients using the live-attenuated varicella vaccine is generally contraindicated, leaving no widely applicable immunization option. The recombinant subunit herpes zoster vaccine (RZV) is indicated for VZV-seropositive persons to prevent shingles but could potentially also protect VZV-seronegative persons against varicella. We performed a safety and immunogenicity evaluation of RZV in VZV-seronegative SOT recipients as an option for protection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>VZV-seronegative adult SOT patients with no history of varicella\/shingles vaccine or disease were given 2 doses of RZV vaccine 2\u20136 mo apart. Blood was drawn prevaccination (V1), before the second dose (V2), and 4 wk after the second dose (V3). Humoral immunity (anti-glycoprotein E) and cell-mediated immunity were evaluated, with polyfunctional cells defined as cells producing \u22652 cytokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Among 31 eligible VZV-seronegative SOT patients screened, 23 were enrolled. Median age was 38 y and median time since transplant procedure was 3.8 y. The most frequent transplant types were liver (35%) and lung (30%). Median anti-glycoprotein E levels significantly increased from V1 to V3 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.001) and V2 to V3 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001), even though only 55% had a positive seroresponse. Median polyfunctional CD4 T-cell counts increased from V1 to V2 (54\/10\n                      <jats:sup>6<\/jats:sup>\n                      versus 104\/10\n                      <jats:sup>6<\/jats:sup>\n                      cells;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.041) and from V2 to V3 (380\/10\n                      <jats:sup>6<\/jats:sup>\n                      ;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.002). Most adverse events were mild with no rejection episodes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>RZV was safe and elicited significant humoral and cellular responses in VZV-seronegative SOT patients and has the potential to be considered as a preventive strategy against primary varicella.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000003621","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T16:48:02Z","timestamp":1611247682000},"page":"2316-2323","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":50,"title":["Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients"],"prefix":"10.1097","volume":"105","author":[{"given":"Arnaud G.","family":"L'Huillier","sequence":"first","affiliation":[{"name":"Pediatric Infectious Diseases Unit, Department of Women, Child and Adolescent Medicine, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Hirzel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Inselspital, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ierullo","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrance","family":"Ku","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Selzner","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schiff","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Juvet","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congrong","family":"Miao","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"Schmid","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Humar","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-3476(81)80527-6","article-title":"Varicella in children with renal transplants.","volume":"98","author":"Feldhoff","year":"1981","journal-title":"J Pediatr"},{"issue":"Pt 1","key":"R2-20250607","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1542\/peds.90.2.216","article-title":"Varicella in pediatric renal transplant recipients.","volume":"90","author":"Lynfield","year":"1992","journal-title":"Pediatrics"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/00007890-200202270-00023","article-title":"Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature.","volume":"73","author":"Fehr","year":"2002","journal-title":"Transplantation"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1046\/j.1600-6143.2003.00287.x","article-title":"Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era.","volume":"4","author":"Gourishankar","year":"2004","journal-title":"Am J Transplant"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.athoracsur.2008.11.004","article-title":"Herpes zoster after lung transplantation: incidence, timing, and outcome.","volume":"87","author":"Fuks","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"e13563","DOI":"10.1111\/ctr.13563","article-title":"Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Danziger-Isakov","year":"2019","journal-title":"Clin Transplant"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial.","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase \u00bd study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study.","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older.","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1177\/003335491012500613","article-title":"Varicella seroprevalence in the U.S.: data from the National Health and Nutrition Examination Survey, 1999-2004.","volume":"125","author":"Reynolds","year":"2010","journal-title":"Public Health Rep"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10875-010-9490-6","article-title":"H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.","volume":"31","author":"Moris","year":"2011","journal-title":"J Clin Immunol"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1600-6143.2003.00337.x","article-title":"Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.","volume":"4","author":"Salvadori","year":"2004","journal-title":"Am J Transplant"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"e13571","DOI":"10.1111\/petr.13571","article-title":"Live vaccines after pediatric solid organ transplant: proceedings of a consensus meeting, 2018.","volume":"23","author":"Suresh","year":"2019","journal-title":"Pediatr Transplant"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1128\/jvi.66.6.3643-3651.1992","article-title":"Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI.","volume":"66","author":"Litwin","year":"1992","journal-title":"J Virol"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"7951","DOI":"10.1128\/jvi.69.12.7951-7959.1995","article-title":"Envelopment of varicella-zoster virus: targeting of viral glycoproteins to the trans-Golgi network.","volume":"69","author":"Zhu","year":"1995","journal-title":"J Virol"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1016\/j.transproceed.2006.10.090","article-title":"Varicella zoster virus serostatus before and after kidney transplantation, and vaccination of adult kidney transplant candidates.","volume":"38","author":"Geel","year":"2006","journal-title":"Transplant Proc"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1399-3046.2005.00279.x","article-title":"Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients.","volume":"9","author":"Chaves","year":"2005","journal-title":"Pediatr Transplant"},{"issue":"Suppl 2","key":"R22-20250607","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1086\/529448","article-title":"Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella.","volume":"197","author":"Breuer","year":"2008","journal-title":"J Infect Dis"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"e1002367","DOI":"10.1371\/journal.ppat.1002367","article-title":"CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection.","volume":"7","author":"Haberthur","year":"2011","journal-title":"Plos Pathog"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2011.052597","article-title":"Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation.","volume":"97","author":"Kleemann","year":"2012","journal-title":"Haematologica"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"11990","DOI":"10.1128\/JVI.79.18.11990-12001.2005","article-title":"The extracellular domain of herpes simplex virus gE is indispensable for efficient cell-to-cell spread: evidence for gE\/gI receptors.","volume":"79","author":"Polcicova","year":"2005","journal-title":"J Virol"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.immuni.2008.02.004","article-title":"The fidelity, occasional promiscuity, and versatility of T cell receptor recognition.","volume":"28","author":"Godfrey","year":"2008","journal-title":"Immunity"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/cid\/cix1082","article-title":"A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients.","volume":"66","author":"Natori","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1191\/0961203303lu362xx","article-title":"Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration.","volume":"12","author":"Shodell","year":"2003","journal-title":"Lupus"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/j.1600-6143.2011.03604.x","article-title":"De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients.","volume":"11","author":"Katerinis","year":"2011","journal-title":"Am J Transplant"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"e009264","DOI":"10.1136\/bmjopen-2015-009264","article-title":"Effect of the adjuvanted (AS03) A\/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series.","volume":"6","author":"Cohet","year":"2016","journal-title":"BMJ Open"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.vaccine.2016.05.016","article-title":"Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: a self-controlled case-series.","volume":"34","author":"Dos Santos","year":"2016","journal-title":"Vaccine"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T12:12:01Z","timestamp":1749298321000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003621","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}